Unresectable Merkel Cell Carcinoma clinical trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Studying insurance for skin cancer treatment

This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.

Study of pembrolizumab for different cancers in Japan

This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.

Study of a cancer-killing virus with standard treatments

This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.

Beta-only IL-2 therapy for advanced solid tumors

This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.

Pembrolizumab before surgery for resectable Merkel cell cancer

This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.

Immunotherapy with prednisone and sirolimus for transplant skin cancer

This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.

Study of VET3-TGI for advanced solid tumors

This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.

Personalized immunotherapy prediction for melanoma and other cancers

This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.

IFx-Hu2.0 with pembrolizumab for advanced Merkel cell carcinoma

This trial tests a new drug, IFx-Hu2.0, given alongside the immunotherapy pembrolizumab (Keytruda) for people with advanced or spreading Merkel cell carcinoma (MCC). The goal is to see if the combination helps shrink tumors and slow the disease.

Vaccine plus immunotherapy for Merkel cell cancer

This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.

TIL Therapy for Advanced Skin Cancer Patients

This study tests a personalized cell therapy called TIL (tumor-infiltrating lymphocytes) for people with advanced skin cancers that have not responded to immunotherapy. Doctors take your tumor cells, grow immune cells from them, and then infuse them back to fight the cancer.